BioNTech SE (BNTX) stock
BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$83.26−1.60 (-1.89%)
Close on Nov 18, 2026Market cap $20.92BP/E –Yield –
BioNTech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€1.40B. The highest annual figure on record is €15.28B in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€1.40B | – |
| FY2024 | Dec 31, 2024 | -€1.31B | -290.4% |
| FY2023 | Dec 31, 2023 | €690.40M | -94.5% |
| FY2022 | Dec 31, 2022 | €12.64B | -17.3% |
| FY2021 | Dec 31, 2021 | €15.28B | – |
| FY2020 | Dec 31, 2020 | -€82.40M | – |
| FY2019 | Dec 31, 2019 | -€181.50M | – |
| FY2018 | Dec 31, 2018 | -€53.85M | – |
| FY2017 | Dec 31, 2017 | -€61.28M | – |
See a number that looks wrong?